166 related articles for article (PubMed ID: 37594109)
21. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
22. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
24. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
25. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
26. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
27. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
28. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
29. Bile acid abnormalities in cholestatic liver diseases.
Salen G; Batta AK
Gastroenterol Clin North Am; 1999 Mar; 28(1):173-93. PubMed ID: 10198784
[TBL] [Abstract][Full Text] [Related]
30. Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.
Ueda H; Honda A; Miyazaki T; Morishita Y; Hirayama T; Iwamoto J; Nakamoto N; Ikegami T
PLoS One; 2022; 17(7):e0271308. PubMed ID: 35819971
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
33. Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk.
Šimják P; Petr T; Kaslová B; Fejfar T; Hůlek P; Pařízek A; Vítek L
Sci Rep; 2022 Nov; 12(1):19543. PubMed ID: 36379995
[TBL] [Abstract][Full Text] [Related]
34. [Measurement of bile acid N-acetylglucosaminides in serum and urine of patients with chronic liver diseases during ursodeoxycholic acid treatment].
Kimura A; Nakamura K; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1995 Mar; 92(3):224-32. PubMed ID: 7731091
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
36. Secondary bile acids and the biliary epithelia: The good and the bad.
Lenci I; Milana M; Signorello A; Grassi G; Baiocchi L
World J Gastroenterol; 2023 Jan; 29(2):357-366. PubMed ID: 36687129
[TBL] [Abstract][Full Text] [Related]
37. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
38. Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70
de Vries HD; Palmiotti A; Li R; Hovingh MV; Mulder NL; Koehorst M; Bloks VW; van Zutphen T; Kuipers F; de Boer JF
Pediatr Res; 2023 May; 93(6):1582-1590. PubMed ID: 36151295
[TBL] [Abstract][Full Text] [Related]
39. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
40. Bile acids: regulation of apoptosis by ursodeoxycholic acid.
Amaral JD; Viana RJ; Ramalho RM; Steer CJ; Rodrigues CM
J Lipid Res; 2009 Sep; 50(9):1721-34. PubMed ID: 19417220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]